Calcium dobesilate for the treatment of chronic venous insufficiency

Brito V, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A
Record ID 32016001107
Spanish
Authors' recommendations: Evidence of moderate quality shows that calcium dobesilate does not have a significant clinical impact on the progress of edema and ulcer healing, when compared with placebo, although it might have some effects in reducing symptoms such as cramps, pain and heaviness in lower extremities. The identified clinical practice guidelines do not recommend the use of calcium dobesilate for the treatment of chronic venous insufficiency. In Argentina, calcium dobesilate is not listed as drugs of regular or chronic use under the mandatory medical program. In the last years, countries such as Spain and France have removed calcium dobesilate from the list of drugs covered by the public healthcare system due to the quality of the evidence available on its efficacy and safety for the treatment of chronic venous insufficiency.
Details
Project Status: Completed
Year Published: 2016
URL for published report: www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Humans
  • Calcium Dobesilate
  • Hemostatics
  • Venous Insufficiency
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.